ATE495253T1 - Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer - Google Patents

Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer

Info

Publication number
ATE495253T1
ATE495253T1 AT07793124T AT07793124T ATE495253T1 AT E495253 T1 ATE495253 T1 AT E495253T1 AT 07793124 T AT07793124 T AT 07793124T AT 07793124 T AT07793124 T AT 07793124T AT E495253 T1 ATE495253 T1 AT E495253T1
Authority
AT
Austria
Prior art keywords
replication
rna aptamer
inhibiting
nucleease
hepatitis
Prior art date
Application number
AT07793124T
Other languages
English (en)
Inventor
Seong-Wook Lee
Kyung-Sook Shin
Jong-Hoon Lim
Young-Joo Lee
Chang-Ho Lee
Original Assignee
Bexcore Co Ltd
Daewon Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bexcore Co Ltd, Daewon Pharm Co Ltd filed Critical Bexcore Co Ltd
Application granted granted Critical
Publication of ATE495253T1 publication Critical patent/ATE495253T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/205—Aptamer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT07793124T 2006-11-28 2007-06-08 Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer ATE495253T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20060118062 2006-11-28
KR1020070054744A KR100861108B1 (ko) 2006-11-28 2007-06-05 씨형 간염 바이러스 레플리콘 증식을 억제하는 알엔에이분해효소 저항성 알엔에이 압타머
PCT/KR2007/002769 WO2008066231A1 (en) 2006-11-28 2007-06-08 Nuclease-resistant rna aptamer inhibiting replication of hepatitis c virus replicon

Publications (1)

Publication Number Publication Date
ATE495253T1 true ATE495253T1 (de) 2011-01-15

Family

ID=39804607

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07793124T ATE495253T1 (de) 2006-11-28 2007-06-08 Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer

Country Status (10)

Country Link
US (1) US8008272B2 (de)
EP (1) EP2092078B1 (de)
JP (1) JP2010510805A (de)
KR (1) KR100861108B1 (de)
CN (1) CN101605908A (de)
AT (1) ATE495253T1 (de)
AU (1) AU2007326284B2 (de)
CA (1) CA2670447C (de)
DE (1) DE602007011972D1 (de)
WO (2) WO2008066230A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010115177A (ja) * 2008-11-14 2010-05-27 Nec Soft Ltd 分解耐性を有するｒｎａアプタマー分子の修飾ヌクレオチド配列の選択方法
WO2010131748A1 (ja) * 2009-05-15 2010-11-18 地方独立行政法人神奈川県立病院機構 ペプチドを認識するアプタマー
JP5967687B2 (ja) * 2009-07-17 2016-08-10 Ｎｅｃソリューションイノベータ株式会社 スフィンゴシルホスホリルコリンに結合するアプタマー分子
KR20120068231A (ko) * 2010-12-17 2012-06-27 한국식품연구원 살모넬라 티피뮤리움 균주의 ｏｍｐＣ단백질에 대해 결합하는 ＲＮＡ 앱타머
RU2501862C1 (ru) * 2012-04-16 2013-12-20 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ Лимнологический институт Сибирского отделения Российской академии наук Способ получения терапевтического агента для лечения клещевого энцефалита
SG10201912895PA (en) 2012-07-13 2020-02-27 Wave Life Sciences Ltd Chiral control
KR101480495B1 (ko) * 2013-04-30 2015-01-12 주식회사 포스코 C형 간염바이러스의 표면 단백질 e2에 대한 압타머 및 이의 용도
WO2016057920A1 (en) * 2014-10-09 2016-04-14 The Research Foundation For The State University Of New York Rna hydrogel
WO2016156335A1 (en) * 2015-04-01 2016-10-06 Universität Wien Novel expression regulating rna-molecules and uses thereof
US10731165B2 (en) 2016-10-06 2020-08-04 The Research Foundation For The State University Of New York RNA hydrogels
CN108330131A (zh) * 2018-01-30 2018-07-27 中国人民解放军军事科学院军事医学研究院 抑制丝状病毒感染的抗病毒包膜糖蛋白的rna适配体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2666142B2 (ja) * 1987-02-04 1997-10-22 旭光学工業株式会社 カメラの自動焦点検出装置
US20050209180A1 (en) 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US7465537B2 (en) 2005-05-01 2008-12-16 The Board Of Trustees Of The University Of Arkansas Compounds and methods for inhibiting hepatitis C virus replication

Also Published As

Publication number Publication date
CA2670447C (en) 2013-02-12
DE602007011972D1 (de) 2011-02-24
KR20080048382A (ko) 2008-06-02
JP2010510805A (ja) 2010-04-08
CN101605908A (zh) 2009-12-16
EP2092078A4 (de) 2010-04-07
US20100160617A1 (en) 2010-06-24
US8008272B2 (en) 2011-08-30
AU2007326284B2 (en) 2012-01-19
AU2007326284A1 (en) 2008-06-05
CA2670447A1 (en) 2008-06-05
EP2092078A1 (de) 2009-08-26
WO2008066230A1 (en) 2008-06-05
WO2008066231A1 (en) 2008-06-05
EP2092078B1 (de) 2011-01-12
KR100861108B1 (ko) 2008-09-30

Similar Documents

Publication Publication Date Title
ATE495253T1 (de) Die replikation des hepatitis-c-virus-replikons hemmendes nukleaseresistentes rna-aptamer
Lau et al. Complete genome analysis of three novel picornaviruses from diverse bat species
DE602004030583D1 (de) Oligonukleotidanalog und verfahren zur behandlung von flavivirusinfektionen
EA201200217A1 (ru) Рнк с комбинацией из немодифицированных и модифицированных нуклеотидов для экспрессии белков
DK1747023T3 (da) Fremgangsmåder og sammensætninger til formindskelse af HCV-virusgenommængder i en målcelle
EA200700243A1 (ru) Способы лечения гепатита с
MY176918A (en) N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production
DK2230304T3 (da) IRNA-modulering af RSV og terapeutiske anvendelser deraf
DE602007006457D1 (de) Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion
ATE507293T1 (de) Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
EP2399575A3 (de) Verfahren, Verwendungen und Zusammensetzungen zur Behandlung einer Infektion durch einen Virus aus der Familie der Flaviviridae durch Hemmung des Farnesoid X-Rezeptors (FXR)
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
DE602008006227D1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
NZ598000A (en) Composition for treating hbv infection
EP2120565A4 (de) Cyclische nukleosid-phosphoramidate für die behandlung von rna-abhängigen rna-virusinfektionen
NZ592203A (en) Modulation of factor 11 expression
JP2012136542A5 (de)
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
NO20052956L (no) Defensinprotiner
DK1749097T3 (da) Replikationskompetente vira, der er i stand til silencing af ekspression af virushæmmende faktor
Sadeghipour et al. Selection and characterisation of guanidine-resistant mutants of human enterovirus 71
EP2325314A3 (de) Targeting von Zwischenprodukten zur Gegenstrangreplikation von einzelstrangigen Viren durch RNAi
EA200401362A1 (ru) Антивирусная терапия, основанная на противодействии рнк
DK1689886T3 (da) Molekylær markör associeret med CMV-resistens og anvendelse deraf
GB2463584A (en) Carbohydrate-lipid constructs and their use in preventing or treating viral infection

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties